Liofora

Drospirenone, the active ingredient in Liofora, is a combined oral contraceptive presented as a Drospirenone 3 mg / Ethinylestradiol 20 µg tablet for oral use. It is indicated for the prevention of pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus.

GNH USA supplies Liofora as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Liofora, a combined oral contraceptive, is used within the hormonal contraceptive pathway to prevent unintended pregnancy.

Prevention of pregnancy: provides reliable contraceptive protection when taken as directed.

Liofora may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: occasional mild to moderate pain. - Spotting or breakthrough bleeding: irregular vaginal bleeding. - Weight gain: modest increase in body weight. - Mood changes: irritability or mood swings.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Arterial thrombosis: stroke or myocardial infarction. - Severe hypertension: significant increase in blood pressure. - Liver disorders: cholestatic jaundice or hepatic dysfunction. - Gallbladder disease: cholelithiasis or cholecystitis. - Severe allergic reaction: anaphylaxis or angioedema.

Before prescribing Liofora, clinicians should evaluate several safety considerations.

Assess cardiovascular risk: review history of thrombosis, smoking status, and age over 35. Review hepatic function: avoid in severe liver disease. Monitor blood pressure: discontinue if hypertension develops. Consider smoking status: avoid in women >35 who smoke. Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Liofora can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce contraceptive effectiveness. - Anticoagulants: may increase bleeding risk.

Moderate Interactions (Monitor Closely): - Other hormonal therapies: may increase overall estrogen exposure. - Antihypertensives: may alter blood pressure control. - Certain antibiotics (e.g., azithromycin): potential uncertain effect on hormone levels.